Table 1.
HDAC6 protein expression in PTs and MLNs and their correlations with clinicopathological features of patients with esophageal squamous cell cancer
| Variables | HDAC6 in PTs | HDAC6 in MLNs | ||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| All | Low, n (%) | High, n (%) | Pa | All | Low, n (%) | High, n (%) | Pa | |
|
| ||||||||
| Gender | 0.587 | 1.000 | ||||||
| Male | 172 | 90 (52.3) | 82 (47.7) | 128 | 65 (50.8) | 63 (49.2) | ||
| Female | 37 | 17 (45.9) | 20 (54.1) | 27 | 14 (51.9) | 13 (48.1) | ||
| Age (years) | 1.000 | 0.149 | ||||||
| ≤60 | 119 | 61 (51.3) | 58 (48.7) | 79 | 45 (57.0) | 34 (43.0) | ||
| >60 | 90 | 46 (51.1) | 44 (48.9) | 76 | 34 (44.7) | 42 (55.3) | ||
| Smoking | 0.711 | 0.384 | ||||||
| Yes | 150 | 78 (52.0) | 72 (48.0) | 113 | 60 (53.1) | 53 (46.9) | ||
| No | 59 | 29 (49.2) | 30 (50.8) | 42 | 19 (45.2) | 23 (54.8) | ||
| Drinking | 0.239 | 0.131 | ||||||
| Yes | 76 | 43 (56.6) | 33 (43.4) | 54 | 32 (59.3) | 22 (40.7) | ||
| No | 133 | 64 (48.1) | 69 (51.9) | 101 | 47 (46.5) | 54 (53.5) | ||
| Location | 0.591 | 0.508 | ||||||
| Upper | 19 | 8 (42.1) | 11 (57.9) | 13 | 5 (38.5) | 8 (61.5) | ||
| Middle | 119 | 60 (50.4) | 59 (49.6) | 92 | 46 (50.0) | 46 (50.0) | ||
| Lower | 71 | 39 (54.9) | 32 (45.1) | 50 | 28 (56.0) | 22 (44.0) | ||
| Length (cm) | 1.000 | 1.000 | ||||||
| ≤5.0 | 110 | 56 (50.9) | 54 (49.1) | 80 | 41 (51.3) | 39 (48.8) | ||
| >5.0 | 99 | 51 (51.5) | 48 (48.5) | 75 | 38 (50.7) | 37 (49.3) | ||
| Grade | 0.557 | 0.585 | ||||||
| I | 43 | 25 (58.1) | 18 (41.9) | 35 | 19 (54.3) | 16 (45.7) | ||
| II | 101 | 51 (50.5) | 50 (49.5) | 73 | 39 (53.4) | 34 (46.6) | ||
| III | 65 | 31 (47.7) | 34 (52.3) | 47 | 21 (44.7) | 26 (55.3) | ||
| N stage | 0.394 | 0.571 | ||||||
| N1 | 118 | 63 (53.4) | 55 (46.6) | 74 | 41 (55.4) | 33 (44.6) | ||
| N2 | 69 | 31 (44.9) | 38 (55.1) | 60 | 28 (46.7) | 32 (53.3) | ||
| N3 | 22 | 13 (59.1) | 9 (40.9) | 21 | 10 (47.6) | 11 (52.4) | ||
Note:
a
Pearson’s chi-squared test.
Abbreviations: HDAC6, histone deacetylase 6; MLN, metastatic lymph node; PT, primary tumor.